• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. Exciton manipulation in rippled transition metal dichalcogenides?
  Chen Long,Ying Dai,Jianwei Li,Hao Jin Nanoscale, 2020,12, 21124-21130
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Halobenzoic acids and derivatives

Research Brief on N-Cyclopentyl 4-bromobenzamide (CAS: 223557-21-9): Recent Advances and Applications

N-Cyclopentyl 4-bromobenzamide (CAS: 223557-21-9) is a brominated aromatic amide compound that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential as a versatile building block for drug discovery and development. Recent studies have highlighted its utility in the synthesis of bioactive molecules, particularly in the context of kinase inhibitors and other targeted therapies. This research brief provides an overview of the latest findings related to this compound, focusing on its synthetic applications, biological activities, and potential therapeutic implications.

One of the key areas of interest in recent research has been the role of N-Cyclopentyl 4-bromobenzamide as an intermediate in the synthesis of kinase inhibitors. Kinases are critical regulators of cellular signaling pathways, and their dysregulation is implicated in numerous diseases, including cancer and inflammatory disorders. Researchers have utilized the bromo-substituted aromatic ring of this compound to facilitate cross-coupling reactions, such as Suzuki-Miyaura and Buchwald-Hartwig couplings, enabling the efficient construction of complex heterocyclic scaffolds. These scaffolds have shown promising activity against various kinase targets, including EGFR, BRAF, and CDK4/6.

In addition to its synthetic utility, N-Cyclopentyl 4-bromobenzamide has been investigated for its direct biological effects. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit moderate inhibitory activity against certain isoforms of phosphodiesterase (PDE), an enzyme family involved in cyclic nucleotide signaling. This finding suggests potential applications in the treatment of cardiovascular and neurological disorders, where PDE modulation is a well-established therapeutic strategy. Further structure-activity relationship (SAR) studies are underway to optimize the potency and selectivity of these derivatives.

Another notable development is the use of N-Cyclopentyl 4-bromobenzamide in the design of proteolysis-targeting chimeras (PROTACs). PROTACs are bifunctional molecules that recruit E3 ubiquitin ligases to target proteins for degradation, offering a novel approach to drug discovery. Researchers have incorporated this compound into PROTACs targeting oncogenic proteins, leveraging its bromo group for further functionalization. Preliminary results indicate that these PROTACs exhibit enhanced degradation efficiency compared to traditional small-molecule inhibitors, highlighting the compound's potential in next-generation therapeutics.

Despite these advancements, challenges remain in the development of N-Cyclopentyl 4-bromobenzamide-based therapeutics. Issues such as solubility, metabolic stability, and off-target effects need to be addressed through further medicinal chemistry optimization. Recent efforts have focused on introducing polar substituents or prodrug strategies to improve pharmacokinetic properties. Additionally, computational modeling and high-throughput screening are being employed to identify novel derivatives with improved efficacy and safety profiles.

In conclusion, N-Cyclopentyl 4-bromobenzamide (CAS: 223557-21-9) continues to be a valuable tool in chemical biology and drug discovery. Its versatility as a synthetic intermediate and its emerging biological activities make it a compound of significant interest for researchers. Future studies will likely explore its applications in additional therapeutic areas and further refine its derivatives for clinical translation. This brief underscores the importance of ongoing research to fully realize the potential of this promising molecule.

• 503464-88-8(3-Bromo-N-4-Piperidinyl-Benzamide)
• 315706-68-4(Benzamide,4-bromo-N-(4-propylcyclohexyl)-)
• 59507-55-0(N-Cyclohexyl 3-bromobenzamide)
• 223553-87-5(N-Cyclohexyl 4-bromobenzamide)
• 149556-35-4(Benzamide, 4-bromo-N-cyclohexyl-N-(1-methylethyl)-)
• 149556-36-5(Benzamide, 4-bromo-N-cyclohexyl-N-cyclopentyl-)
• 327058-58-2(4-bromo-n,n-dicyclohexylbenzamide)
• 331256-17-8((4-bromophenyl)(2-methyl-1-piperidinyl)methanone)
• 1020252-78-1(N-Cyclopentyl 4-bromo-3-methylbenzamide)
• 349405-34-1(3-Bromo-N-cyclopentylbenzamide)